Theravance Biopharma, Inc.
DE ˙ DB ˙ KYG8807B1068
13,90 € ↑0,30 (2,21%)
2026-06-05
DEL PRIS
SecurityDE:0TB / Theravance Biopharma, Inc.
InstitutionNorthern Trust Corp
Latest Disclosed Ownership370,534 shares
Latest Disclosed Value $ 6,013,767
Northern Trust Corp reports 12.31% increase in ownership of 0TB / Theravance Biopharma, Inc.

On May 14, 2026 - Northern Trust Corp filed a 13F-HR form disclosing ownership of 370,534 shares of Theravance Biopharma, Inc. (DE:0TB) valued at $4,891,049 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 329,927 shares of Theravance Biopharma, Inc.. This represents a change in shares of 12.31% during the quarter. The current value of the position is $5,150,423 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 370,534 40,607 12.31 6,014 -2.58 0.0008
2026-02-17 2025-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 329,927 -11,379 -3.33 6,173 23.86 0.0008
2025-11-14 2025-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 341,306 -10,919 -3.10 4,983 28.26 0.0006
2025-08-13 2025-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 352,225 2,808 0.80 3,885 24.52 0.0005
2025-05-13 2025-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 349,417 -40,563 -10.40 3,120 -14.96 0.0005
2025-02-14 2024-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 389,980 6,198 1.61 3,670 18.62 0.0005
2024-11-13 2024-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 383,782 -81,185 -17.46 3,093 -21.54 0.0005
2024-08-14 2024-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 464,967 -23,785 -4.87 3,943 -10.08 0.0007
2024-05-14 2024-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 488,752 -33,184 -6.36 4,384 -25.26 0.0008
2024-02-13 2023-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 521,936 -34,459 -6.19 5,867 22.18 0.0011
2023-11-13 2023-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 556,395 -61,113 -9.90 4,802 -24.88 0.0009
2023-08-11 2023-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 617,508 -30,571 -4.72 6,391 -9.10 0.0012
2023-05-15 2023-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 648,079 11,674 1.83 7,032 -1.53 0.0014
2023-02-13 2022-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 636,405 38,102 6.37 7,140 17.69 0.0015
2022-11-14 2022-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 598,303 3,069 0.52 6,067 12.50 0.0014
2022-08-12 2022-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 595,234 6,181 1.05 5,393 -4.23 0.0012
2022-05-13 2022-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 589,053 -25,308 -4.12 5,631 -17.04 0.0010
2022-02-08 2021-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 614,361 11,723 1.95 6,788 52.23 0.0011
2021-11-15 2021-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 602,638 41,705 7.43 4,459 -45.25 0.0008
2021-08-13 2021-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 560,933 41,703 8.03 8,144 -23.16 0.0014
2021-05-12 2021-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 519,230 -19,462 -3.61 10,598 10.71 0.0020
2021-02-11 2020-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 538,692 -65,010 -10.77 9,573 7.26 0.0019
2020-11-16 2020-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 603,702 -29,626 -4.68 8,925 -32.87 0.0020
2020-08-14 2020-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 633,328 11,158 1.79 13,295 -7.53 0.0031
2020-05-14 2020-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 622,170 50,594 8.85 14,378 -2.84 0.0041
2020-02-14 2019-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 571,576 -6,094 -1.05 14,798 31.50 0.0033
2019-11-13 2019-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 577,670 24,041 4.34 11,253 24.47 0.0027
2019-08-13 2019-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 553,629 3,547 0.64 9,041 -27.50 0.0021
2019-05-13 2019-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 550,082 -714 -0.13 12,471 -11.52 0.0031
2019-02-12 2018-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 550,796 4,274 0.78 14,095 -21.06 0.0040
2018-11-14 2018-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 546,522 11,238 2.10 17,855 47.08 0.0044
2018-09-18 2018-06-30 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 535,284 18,733 3.63 12,140 -3.08 0.0031
2018-08-14 2018-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 538,847 22,296 12,221
2018-05-09 2018-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 516,551 4,509 0.88 12,526 -12.30 0.0033
2018-02-14 2017-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 512,042 -14,253 -2.71 14,282 -20.74 0.0036
2017-11-13 2017-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 526,295 -3,754 -0.71 18,020 -14.67 0.0047
2017-08-11 2017-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 530,049 30,611 6.13 21,117 14.84 0.0059
2017-05-12 2017-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 499,438 25,884 5.47 18,388 21.80 0.0053
2017-02-13 2016-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 473,554 48,560 11.43 15,097 -1.99 0.0046
2016-11-09 2016-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 424,994 274,760 182.89 15,403 351.70 0.0048
2016-08-12 2016-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 150,234 -163,078 -52.05 3,410 -42.11 0.0011
2016-08-19 2016-03-31 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 313,312 8,898 2.92 5,890 18.06 0.0020
2016-05-13 2016-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 313,312 5,890
2016-02-12 2015-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 304,414 42,347 16.16 4,989 73.23 0.0017
2015-11-12 2015-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 262,067 262,067 0.00 2,880 0.0010
2015-08-13 2015-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 0 -260,726 -100.00 0 -100.00
2015-05-14 2015-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 260,726 12,884 5.20 4,524 22.34 0.0014
2015-02-12 2014-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 247,842 -17,694 -6.66 3,698 -39.59 0.0011
2014-11-13 2014-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 265,536 152,158 134.20 6,121 69.32 0.0019
2014-08-14 2014-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 113,378 113,378 3,615 0.0011
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.